Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Multi-Line Therapy Trial in Unresectable Wild-Type KRAS Metastatic Colorectal Cancer (GERCOR Phase III)
2013-001928-19Phase 3Active
- Sponsor
- GERCOR
- Start
- May 2013
- Modality
- Small Molecules, Monoclonal Antibodies → Antibody-Based Therapeutics, Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of cetuximab, bevacizumab, panitumumab, irinotecan, oxaliplatin and 2 more in colorectal cancer (CRC) and metastatic colorectal adenocarcinoma (mCRC) (2 arms), sponsored by GERCOR. Primary endpoint: duration of disease control. Started May 2013; status: active.
02
Drugs
cetuximabbevacizumabpanitumumabirinotecanoxaliplatin
03
Conditions
colorectal cancer (CRC)metastatic colorectal adenocarcinoma (mCRC)
Beyond the preview
Go deeper on 2013-001928-19.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2013-001928-19.